Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04860869 · ClinicalTrials.gov registry record
Endocrine, Metabolic and Microbiome Influence on the Post-acute Sequelae SARS-CoV-2 (PASC)
A clinical trial, sponsored by The University of Texas Medical Branch, Galveston.
- Completed
- Registry status
- 23
- Enrollment target
NCT04860869 is a clinical trial that has completed, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 23 participants.
The verdict
NCT04860869 has completed, sponsored by The University of Texas Medical Branch, Galveston.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
The aim of this study is characterize the endocrine, metabolic and microbiomes of patients with post-acute sequelae SARS-CoV-2 infection (PASC) and patients that have recovered from COVID without lingering symptoms.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2021-05-12 |
| Est. Completion | 2022-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04860869
The ClinicalTrials.gov registry entry for NCT04860869 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04860869 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04860869 about?
NCT04860869 is a clinical study titled "Endocrine, Metabolic and Microbiome Influence on the Post-acute Sequelae SARS-CoV-2 (PASC)". The aim of this study is characterize the endocrine, metabolic and microbiomes of patients with post-acute sequelae SARS-CoV-2 infection (PASC) and patients that have recovered from COVID without lingering symptoms.
What is the current status of trial NCT04860869?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2021-05-12. Estimated completion is 2022-05-31.
Who is sponsoring clinical trial NCT04860869?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.